caa a22 4500 477057357 CHVBK 20180405111350.0 cr unu---uuuuu 170330e19960601xx s 000 0 eng 10.1007/s002280050105 doi (NATIONALLICENCE)springer-10.1007/s002280050105 Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure [Elektronische Daten] [Y. M. Pinto, D. J. van Veldhuisen, R. T. Tjon-Ka-Jie, G. Rooks, T. Netzer, K. I. Lie] Objective: To study the haemodynamic profile and tolerability of imidapril, a new long-acting ACE inhibitor, and to investigate the effect of inhibition of circulating ACE on blood pressure in patients with stable chronic heart failure. Methods: Twenty-four patients with stable, chronic heart failure (New York Heart Association (NYHA) functional Class II-III) were randomised to receive either 2.5 mg or 5 mg imidapril. Other vasodilators were withheld for ≥ 5 half-lives. Blood pressure and ACE activity were carefully monitored for 24 h after dosing. Results: Both 2.5 mg and 5 mg imidapril decreased systolic blood pressure, while diastolic blood pressure fell only after 5 mg imidapril. The two doses produced a significant and similar inhibition of circulating (serum) ACE. No serious adverse effects were observed, although symptomatic hypotension occurred in 1 patient (5 mg). The decrease in blood pressure was not related to baseline ACE activity, serum sodium or serum creatinine concentration. Conclusions: Imidapril significantly lowered systolic blood pressure and was well tolerated. The difference in the first dose response to the two doses with respect to diastolic blood pressure suggests that this haemodynamic effect of ACE-inhibition is not related to inhibition of circulating ACE. Springer-Verlag Berlin Heidelberg, 1996 Key words Imidapril nationallicence Angiotensin converting enzyme nationallicence Heart failure nationallicence ACE inhibitor nationallicence blood pressure nationallicence circulating ACE nationallicence Pinto Y. M. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut van Veldhuisen D. J. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut Tjon-Ka-Jie R. T. Department of Cardiology, Scheperziekenhuis, Emmen, The Netherlands, NL aut Rooks G. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut Netzer T. E. Merck, Clinical Research, Darmstadt, Germany, DE aut Lie K. I. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut https://doi.org/10.1007/s002280050105 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050105 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pinto Y. M. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut NATIONALLICENCE 700 1- van Veldhuisen D. J. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut NATIONALLICENCE 700 1- Tjon-Ka-Jie R. T. Department of Cardiology, Scheperziekenhuis, Emmen, The Netherlands, NL aut NATIONALLICENCE 700 1- Rooks G. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut NATIONALLICENCE 700 1- Netzer T. E. Merck, Clinical Research, Darmstadt, Germany, DE aut NATIONALLICENCE 700 1- Lie K. I. Department of Cardiology/Thoraxcenter and Department of Clinical Pharmacology, University Hospital Groningen, Groningen, P.O. Box 30.001, 4700RB The Netherlands, NL aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer